200 related articles for article (PubMed ID: 14633791)
1. Hematopoietic cell transplantation for benign hematological disorders and solid tumors.
Storb RF; Lucarelli G; McSweeney PA; Childs RW
Hematology Am Soc Hematol Educ Program; 2003; ():372-97. PubMed ID: 14633791
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
4. New approaches to hematopoietic cell transplantation for hematological diseases in children.
Woodard P; Lubin B; Walters CM
Pediatr Clin North Am; 2002 Oct; 49(5):989-1007. PubMed ID: 12430622
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.
Sullivan KM; Muraro P; Tyndall A
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S48-56. PubMed ID: 19895895
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation for severe autoimmune diseases: progress and problems.
Marmont AM
Haematologica; 1998 Aug; 83(8):733-43. PubMed ID: 9793258
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions.
Lundqvist A; Childs R
J Immunother; 2005; 28(4):281-8. PubMed ID: 16000944
[TBL] [Abstract][Full Text] [Related]
8. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
Maris MB; Storb R
Acta Haematol; 2005; 114(4):221-9. PubMed ID: 16269862
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cell transplantation: five decades of progress.
Baron F; Storb R; Little MT
Arch Med Res; 2003; 34(6):528-44. PubMed ID: 14734093
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy.
Childs R; Barrett J
Semin Hematol; 2002 Jan; 39(1):63-71. PubMed ID: 11799531
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders.
Baron F; Storb R
Mol Ther; 2006 Jan; 13(1):26-41. PubMed ID: 16280257
[TBL] [Abstract][Full Text] [Related]
15. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.
Passweg JR; Baldomero H; Basak GW; Chabannon C; Corbacioglu S; Duarte R; Kuball J; Lankester A; Montoto S; de Latour RP; Snowden JA; Styczynski J; Yakoub-Agha I; Arat M; Mohty M; Kröger N;
Bone Marrow Transplant; 2019 Oct; 54(10):1575-1585. PubMed ID: 30728439
[TBL] [Abstract][Full Text] [Related]
16. New approaches to hematopoietic cell transplantation in oncology.
Reiss U; Bolotin E
Pediatr Clin North Am; 2002 Dec; 49(6):1437-66. PubMed ID: 12580373
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation: a new strategy for intractable diseases.
Ikehara S
Drugs Today (Barc); 2002 Feb; 38(2):103-11. PubMed ID: 12532188
[TBL] [Abstract][Full Text] [Related]
18. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
20. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
